Peter Attia· MD
So rapamycin would go on to be approved by the FDA in 1999 as a frontline treatment as part of the double or triple cocktail for patients. As rapimmune, right? As rapimmune along with often prednisone, cyclosporine or MMF.
Loading…
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
So rapamycin would go on to be approved by the FDA in 1999 as a frontline treatment as part of the double or triple cocktail for patients. As rapimmune, right? As rapimmune along with often prednisone, cyclosporine or MMF.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
the FDA approval for rapamycin in humans was 1999.
the first paper that seren Segal put out there describing the chemical composition of rapamycin if I'm not mistaken was about 1971 1972 the FDA approval for rapamycin in humans was 1999.
and it spends the next decade in relative obscurity
so in 1999 the FDA approves this drug for organ transplantation solid organ transplantation
ultimately that drug which almost died a thousand deaths due to lack of interest um finally uh was championed through a guy named saren Seagal who has since passed away and and saren single-handedly basically figured out utility for this drug that ultimately put it uh on the map as a drug that found its ultim ultimate clinical application in organ transplantation as an immune suppressant so in 1999 the FDA approves this drug for organ transplantation solid organ transplantation
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.